Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Azathioprine
Drug ID BADD_D00195
Description Azathioprine is a prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings in an attempt to produce a derivative of 6-mercaptopurine with a better therapeutic index.[A189678,A189687,A189690] Azathioprine is used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection.[L11214] Azathiprine was granted FDA approval on 20 March 1968.[L11214]
Indications and Usage Azathioprine is indicated to treat rheumatoid arthritis and prevent renal transplant rejection.[L11214]
Marketing Status approved
ATC Code L04AX01
DrugBank ID DB00993
KEGG ID D00238
MeSH ID D001379
PubChem ID 2265
TTD Drug ID D07QCE
NDC Product Code 62991-2189; 65649-231; 67877-492; 68084-229; 68382-120; 51407-182; 68382-118; 72789-129; 46014-1110; 70771-1141; 60219-1076; 60219-2036; 60219-2037; 68382-003; 48954-909; 51927-0071; 68682-241; 70518-3544; 70771-1140; 51927-2258; 54766-590; 65841-602; 12780-0300; 38779-0312; 66122-0009; 42291-063; 68462-502; 71610-124; 42291-071; 68682-231; 70771-1139; 15308-0732; 49452-0783; 67877-493; 51552-0779; 65649-241; 67877-494; 67877-495; 68382-119; 42973-143
UNII MRK240IY2L
Synonyms Azathioprine | Azothioprine | Imurel | Imuran | Immuran | Azathioprine Sodium | Sodium, Azathioprine | Azathioprine Sodium Salt | Azathioprine Sulfate
Chemical Information
Molecular Formula C9H7N7O2S
CAS Registry Number 446-86-6
SMILES CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Live birth18.08.02.0070.003384%Not Available
SAPHO syndrome23.03.10.005; 15.03.03.013; 10.02.01.0640.000470%Not Available
Focal nodular hyperplasia16.06.01.004; 09.04.01.0040.000313%Not Available
Morton's neuralgia17.02.07.0220.000313%Not Available
Small intestinal haemorrhage24.07.02.019; 07.12.03.0020.000313%
Facet joint syndrome17.10.01.015; 15.01.08.010--Not Available
Pseudopolyp08.01.05.0150.000470%Not Available
Cell death14.11.02.005; 08.03.03.0030.000313%Not Available
Neuroendocrine carcinoma16.24.01.007; 05.08.01.0110.000627%Not Available
Gastrointestinal oedema07.11.01.0120.001410%Not Available
Female genital tract fistula21.10.05.009; 07.11.05.004; 20.08.01.007; 12.02.14.010; 23.07.04.0150.000627%Not Available
Small intestinal stenosis07.13.06.0080.002193%
Enterovesical fistula20.03.01.021; 07.11.05.009--
Myasthenia gravis crisis17.05.04.007; 10.04.05.007; 15.05.08.0040.001097%Not Available
Dysplastic naevus23.10.01.011; 16.26.01.0110.000470%Not Available
Subretinal fibrosis06.09.03.0260.000313%Not Available
Metastatic squamous cell carcinoma16.16.01.0100.000313%Not Available
Rectal fissure07.03.01.007--
Plasmablastic lymphoma01.17.01.004; 16.35.01.0040.000470%Not Available
Vaginal fistula21.08.01.014--
Fistula of small intestine12.02.03.026; 07.11.05.0100.000470%
Fistula discharge15.03.02.015; 08.01.03.0690.000783%Not Available
Subchorionic haemorrhage24.07.03.030; 18.02.01.007--Not Available
Epstein-Barr virus associated lymphoma01.15.01.003; 16.28.01.003; 11.05.10.0070.000783%Not Available
Spinal pain08.01.08.030; 17.10.01.020; 15.02.01.008--Not Available
Prerenal failure24.06.02.025; 20.01.03.0220.000313%Not Available
Intestinal fibrosis07.13.01.0130.001097%Not Available
Invasive ductal breast carcinoma16.10.01.013; 21.05.01.0210.000313%Not Available
Anal squamous cell carcinoma16.13.05.002; 07.21.05.0040.000313%Not Available
Small intestine adenocarcinoma16.13.13.001; 07.21.01.0150.000313%Not Available
The 23th Page    First    Pre   23 24 25    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene